Vera Therapeutics

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immunological diseases to improve patients' lives, with a particular emphasis on setting the standard in IgA Nephropathy (IgAN).

Products & Services

Atacicept in IgAN:A treatment being developed for IgA Nephropathy, with Phase 2b clinical data and an ongoing Phase 3 clinical trial.

Atacicept in LN:A treatment under development for Lupus Nephritis (LN).

MAU868:A therapeutic product candidate, specifics not detailed in the content.

Specialties

Immunological Diseases IgA Nephropathy (IgAN) Lupus Nephritis (LN) Clinical-Stage Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 261000000 MR: - FA: approximately $261 million FAN: 261000000	D: 2025-12-09 FD: 2025-12-09	5 investors
2	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: 200.0 million FAN: 200000000	D: 2025-12-08 FD: 2025-12-08	5 investors
3	RT: Debt T: - FT: Debt	A: 500000000 MR: - FA: up to $500 million FAN: 500000000	D: 2025-06-03 FD: 2025-06-03	1 investors
4	RT: Public Offering T: - FT: Public Offering	A: 300000000 MR: - FA: $300.0 million FAN: 300000000	D: 2024-10-29 FD: 2024-10-29	4 investors
5	RT: Public Offering of Class A Common Stock T: - FT: Public Offering of Class A Common Stock	A: 300000000 MR: - FA: $300.0 million FAN: 300000000	D: 2024-10-28 FD: 2024-10-28	4 investors
6	RT: Public Offering of Class A Common Stock T: - FT: Public Offering of Class A Common Stock	A: 287500000 MR: - FA: $287.5 million FAN: 287500000	D: 2024-02-01 FD: 2024-02-01	4 investors
7	RT: Public Offering T: - FT: Public Offering	A: 250000000 MR: - FA: $250.0 million FAN: 250000000	D: 2024-01-29 FD: 2024-01-29	4 investors
8	RT: Public Offering of Class A Common Stock T: - FT: Public Offering of Class A Common Stock	A: 200000000 MR: - FA: $200.0 million FAN: 200000000	D: 2024-01-29 FD: 2024-01-29	4 investors
9	RT: Public Offering T: - FT: Public Offering	A: 115000000 MR: - FA: approximately $115.0 million FAN: 115000000	D: 2023-02-06 FD: 2023-02-06	4 investors
10	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: 100.0 million FAN: 100000000	D: 2023-02-01 FD: 2023-02-01	4 investors
11	RT: Public Offering T: - FT: Public Offering	A: 75000000 MR: - FA: 75.0 million FAN: 75000000	D: 2023-02-01 FD: 2023-02-01	4 investors

Public Offering Latest

2025-12-09

$261.0M

5 investors (Pro only)

Public Offering 2025-12-08

$200.0M

Debt 2025-06-03

$500.0M

View 10 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Marshall Fordyce

CEO and Founder

R

Robert M. Brenner

Chief Medical Officer

J

Jason Carter

Chief Legal Officer

L

Lauren Frenz

Chief Business Officer

S

Sean Grant

Chief Financial Officer

D

David Johnson

Chief Operating Officer

View 41 more team members with Pro

Unlock Full Team Directory

Recent News